Figure 3.

Impact of PPFs of PK origin by proactive TDM and prior biologics on CRP-based clinical remission status by exposure during maintenance. Estimates are as follows: θ_pop = 0.3 ± 0.4 (p = 0.453); θ_cov, prior biologics = −1.7 ± 0.5 (p = 0.001); θ_cov, PPFs of PK origin >0 = −0.9 ± 0.4 (p = 0.024); θ_cov, proactive TDM = 1.4 ± 0.3 (p< 0.001); θ_{concentrations} = 0.07 ± 0.01 (p< 0.001). (A) Probability of CRP-based clinical remission in patients naïve to biologics. (B) Probability of CRP-based clinical remission in patients with prior biologics. PPF, poor prognostic factor; PK, pharmacokinetic; TDM, therapeutic drug monitoring; CRP, C-reactive protein.